We have systematically discussed the association between the TRIP13 expression level and clinical prognosis, tumor microenvironment (TME), DNA methylation, tumor mutational burden (TMB), microsatellite instability (MSI), and drug sensitivity in 33 cancers. Here, TRIP13 is linked to cancer.